Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $223.62 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Celcuity LLC had its IPO on 2017-09-20 under the ticker symbol CELC.
The company operates in the Healthcare sector and Biotechnology industry. Celcuity LLC has a staff strength of 45 employees.
Shares of Celcuity LLC opened at $10.47 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $10.25 - $10.98, and closed at $10.36.
This is a +0.44% increase from the previous day's closing price.
A total volume of 245,111 shares were traded at the close of the day’s session.
In the last one week, shares of Celcuity LLC have increased by +3.45%.
Celcuity LLC's Key Ratios
Celcuity LLC has a market cap of $223.62 million, indicating a price to book ratio of 3.3317 and a price to sales ratio of 0.
In the last 12-months Celcuity LLC’s revenue was $0 with a gross profit of $0 and an EBITDA of $-39180172. The EBITDA ratio measures Celcuity LLC's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Celcuity LLC’s operating margin was 0% while its return on assets stood at -18.82% with a return of equity of -39.88%.
In Q4, Celcuity LLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Celcuity LLC’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.46 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Celcuity LLC’s profitability.
Celcuity LLC stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.0746. Its price to sales ratio in the trailing 12-months stood at 0.
Celcuity LLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $175.70 million
- Total Liabilities
- $6.88 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Celcuity LLC ended 2023 with $175.70 million in total assets and $0 in total liabilities. Its intangible assets were valued at $175.70 million while shareholder equity stood at $133.77 million.
Celcuity LLC ended 2023 with $0 in deferred long-term liabilities, $6.88 million in other current liabilities, 21667.00 in common stock, $-96296887.00 in retained earnings and $0 in goodwill. Its cash balance stood at $24.57 million and cash and short-term investments were $168.59 million. The company’s total short-term debt was $194,198 while long-term debt stood at $34.98 million.
Celcuity LLC’s total current assets stands at $175.19 million while long-term investments were $0 and short-term investments were $144.02 million. Its net receivables were $0 compared to accounts payable of $2.63 million and inventory worth $0.
In 2023, Celcuity LLC's operating cash flow was $-143985070.00 while its capital expenditure stood at $112044.
Comparatively, Celcuity LLC paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Celcuity LLC stock is currently trading at $10.36 per share. It touched a 52-week high of $14.402 and a 52-week low of $14.402. Analysts tracking the stock have a 12-month average target price of $24.
Its 50-day moving average was $10.88 and 200-day moving average was $10.11 The short ratio stood at 5.82 indicating a short percent outstanding of 0%.
Around 2292.9% of the company’s stock are held by insiders while 5505.8% are held by institutions.
Frequently Asked Questions About Celcuity LLC
Similar Industry Stocks (Biotechnology)
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company’s CELsignia diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.